Bristol-Myers Unit Settles With Hetero Labs on Pomalyst Patents

Bristol-Myers’s Celgene settled a case with Hetero Labs over nine patents for the cancer drug Pomalyst, ending a lawsuit filed in May 2017 that absorbed actions against other generic-drug makers, all of whom already have settled.

• Hetero is blocked from making copies until patents have expired “unless and to the extent otherwise specifically authorized by Celgene,” according to consent judgment approved Thursday in federal court in Newark, New Jersey
• Celgene and Aurobindo in July settled their part of the dispute, leaving Hetero the only remaining generic-drug maker in consolidated case
• Trial had been set to start in November
• Pomalyst ...